European Primary Care Cardiovascular Society

ESC/EAS statin eligibility in primary prevention may be expanded to high TG levels

Nov. 29, 2017 - Madsen CM et al., Eur Heart J 2017

In a large population-based study, high TG levels identified individuals at high CVD risk, who would not be definite eligible for statin treatment according to the 2016 ESC/EAS guidelines.

Increased mortality risk if initiation of HF therapy is delayed

Nov. 27, 2017 - Zaman S et al., Eur J Heart Fail 2017

Deferral of therapy with ACE inhibitors, beta-blockers, and aldosterone antagonists for 1 year carries an absolute mortality risk of around 1% per month, which is higher than the mortality risk due to therapy mentioned in patient information leaflets.

Lower risk of Parkinson’s Disease seen with statin therapy

Nov. 27, 2017 - Poly TN et al., Neuroepidemiology 2017

In a meta-analysis of 13 observational studies, statin use was associated with a modest reduction in the risk of developing Parkinson’s Disease compared with not using statins.

Slow self-reported walking pace could be used for risk stratification

Nov. 22, 2017 - Yates T et al., Eur Heart J 2017

In the UK Biobank, a slow self-reported walking pace was associated with a higher risk of all-cause and CV mortality in women and men, particularly in those with a low BMI.

LDL-c lowering for primary prevention at high LDL-c may be initiated without risk assessment, according to WOSCOPS analysis

Nov. 21, 2017 - Vallejo-Vaz AJ et al., Circulation 2017

Men with LDL-c levels ≥190 mg/dL without atherosclerotic CVD, have a 2-fold higher risk of major CV events than would be predicted with a risk calculator.

Lower risk of dementia in AF patients treated with oral anticoagulation

Nov. 15, 2017 - Friberg L et al., Eur Heart J 2017

In a large retrospective cohort study, the risk of dementia was higher without oral anticoagulant treatment in patients with AF, compared with AF patients receiving oral anticoagulation.

New ACC/AHA Hypertension Practice Guidelines stress lifestyle improvement and lower SBP target

Nov. 14, 2017 - news

AHA 2017 The new guidelines now define hypertension as >130/80 mmHg, emphasize the need for lifestyle changes and specify details of accurate BP measurement methods. 

In the SPRINT trial, presence or absence of staff did not affect observed CVD risk reduction

Nov. 14, 2017 - news

AHA 2017 A post-hoc survey of the SPRINT examined whether the presence or absence of physician or nursing in the BP measurement changed the treatment effect.

CV benefit seen in CANTOS trial explained by response to anti-inflammatory treatment

Nov. 13, 2017 - news

AHA 2017 A new analysis of CANTOS data shows that patients who achieved hsCRP <2 mg/L benefitted from a 25% reduction in MACE, irrespective of the dose of canakinumab.

Omega-3 carboxylic acids can benefit patients with severe hypertriglyceridemia

Nov. 13, 2017 - Stroes ESG et al., J Clin Lipidol 2017

Patients with SHTG treated with OM3-CA 2 g daily had a statistically significant reduction in TG and non-HDL-c concentrations compared with those treated with olive oil 2 g daily.

Cognitive dysfunction in diabetic patients partly explained by hyperglycemia

Nov. 1, 2017 - Geijselaers SLC et al., Diabetes Care 2017

Differences in cognitive performance between diabetic patients and individuals with normal glucose levels can be explained by hyperglycemia and by BP-related variables, but not by insulin resistance.

Rationale and effect of targeting IL-1beta to lower inflammation and thereby CV events

Oct. 31, 2017 - Libby P. J Am Coll Cardiol. 2017

This review summarizes the rationale to specifically target IL-1beta to lower residual inflammatory risk, now shown to be effective in the CANTOS trial. Other potential targets are also discussed.